Oral MS Drug Data a Mixed Bag at AAN
Two oral multiple sclerosis drugs – Merck Serono’s cladribine and Novartis AG’s FYT720 (fingolimod) – continued to show solid efficacy data but safety concerns prevented either one from emerging as a clear winner at the American Academy of Neurology meeting in Seattle. Both drugs met their [...]